The first group will receive injections of IL-2 maintenance therapy. The second group will receive shots of of IL-12 maintenance therapy. The third group will receive no further therapy. Patients will be divided into two groups. The first group will receive CHOP and rituximab.
Prednisone is given as a shot.
Rituximab is given as an infusion. All participants must be on combination antiretroviral therapy. This trial will study a combination of drugs for the treatment of untreated HIV related non-Hodgkin's lymphoma. Ara-C is also given by intravenous infusion and will be added to the treatment for people whose disease progresses. Whole brain radiation treatment may be required if there is swelling in the brain.